Virtually the same percentage of surveyed rheumatologists selected Enbrel and Humira as the most efficacious agent for the treatment of rheumatoid arthritis
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that virtually the same percentage of surveyed rheumatologists selected Amgen/Pfizer/Takeda's Enbrel and Abbott/Eisai's Humira as the most efficacious agent for the treatment of rheumatoid arthritis.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral agent for the treatment of moderate to severe psoriasis that demonstrates improved efficacy and lasting remission when compared with Amgen/Wyeth/Takeda's Enbrel would earn a higher patient share in the United States than in Europe, according to surveyed US and European dermatologists.